Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.
about
Development of Human Membrane Transporters: Drug Disposition and PharmacogeneticsPropofol: a review of its role in pediatric anesthesia and sedationMaternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literatureDevelopmental pharmacokinetics in pediatric populationsClinical pharmacology of midazolam in neonates and children: effect of disease-a reviewPharmacogenetics-based warfarin dosing in childrenPhysiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.The Simcyp population-based ADME simulatorApproaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric populationTo scale or not to scale: the principles of dose extrapolationScaling and systems biology for integrating multiple organs-on-a-chip.Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataA re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescentsPhysiology-based IVIVE predictions of tramadol from in vitro metabolism data.First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach.Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK modelIn vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3Challenges in conducting clinical trials in children: approaches for improving performanceTips and traps analyzing pediatric PK data.Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.What is the right dose for children?Characterizing variability in warfarin dose requirements in children using modelling and simulation.Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling.The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liverPaediatric pharmacokinetics: key considerations.Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working GroupA bodyweight-dependent allometric exponent for scaling clearance across the human life-span.A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsOptimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.Pharmacokinetic studies in infants using minimal-risk study designsHow to optimize the evaluation and use of antibiotics in neonatesPopulation pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
P2860
Q26786582-16AFB9B1-81D4-4152-AD1D-7D2B94357CB8Q26796361-556F300E-D194-40AA-A6E1-5525F5675E63Q26827698-2CD7CCE1-F1E2-4299-BE56-54D4B95F621CQ27002933-A163DD5B-1D93-4C60-B3F5-C2961C942EE3Q27006333-145A3575-790D-4F48-8D94-DDB442056E6FQ27008320-27886B6C-FC83-4C4D-92CF-1F5C2BCCB194Q27312881-9B4F1DBF-CAD4-42E5-AE26-6631DCDD0F14Q28308225-38B23CFF-9475-4496-A094-2E3E2690F37FQ28389663-E35617E3-3E2C-4BD3-B60D-916787DFFAFDQ28751735-FF26B566-87A2-4AAD-A3EE-15C3726FDA90Q30410626-AF6FA8DA-C5B4-4A9D-AC8D-1D8F7AD4A180Q30666721-26F56884-5574-4420-A5E8-30B68A295A62Q30786488-78FCD5FF-9969-4DCD-9041-3EA5ECA3DC55Q30832465-963F9E1A-216C-46B8-AB08-7B96D171F8C5Q30837825-8D4BB7D9-0AB8-44BE-92E3-B118A155FD5BQ30844731-7A6953C4-76EE-42F7-90F1-6BE8EB29F0C8Q31043972-2B0DFE7E-B4B1-47BF-8321-F6E9618BA9A2Q33574126-53868FE8-781D-42F3-92E0-CCFBCA11A846Q33574651-A9C16ED1-AF11-406F-B917-95638793633CQ33717140-0B381689-132D-4055-80FC-338AFF298D6BQ33820152-DA0477C8-9F9F-4DE7-8832-4BECD97E43E2Q34075909-8B272C04-0D91-4C57-AC4E-55B966D1423DQ34180493-3F03C6EF-159E-4AF0-BD30-F2B2ABC185E7Q34209582-8D7A7BC3-AED7-4587-83C9-BB9190BC45A7Q34393200-4DE2707E-4E82-4D66-B58D-1A2A454ABF89Q34857030-F46C89AB-30D6-41E5-B642-06FB82F819B4Q35135940-96385308-E55D-4549-BDB4-BD29077BC1FFQ35179536-F51FF0ED-A716-41BD-9FB5-56E29C91A063Q35560052-D79EBD60-BAE2-4A8D-8CC8-E7A3EE2AE9A6Q35653564-CDD0A250-E776-4773-A7EA-C4DAF3992118Q35667919-9085E6BA-9403-4DC9-AF39-E263DD5115D3Q35949142-7778E8F2-A227-412E-80A3-D3A4A4F2170BQ36025902-DD70CBB9-365E-4CC8-8908-1B11D9BA8CA1Q36072504-3FDD109F-F31D-4214-A1E5-90207E9DFC3CQ36307045-E541DC82-1F4F-4F43-AC7C-88A36EB3186EQ36336064-08B7BC20-2318-4AA2-B5A8-E44431974B32Q36410220-AA9B87C9-FCD2-49E6-83FB-CAB556D81153Q36438116-FA9851CF-59C0-4093-8B86-C1423A274D9EQ36452369-62D28266-8EB8-4C4C-B84A-E13E5BB83EC0Q36482878-3C6D8109-4ABD-427B-A3E3-64971D813D5C
P2860
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Prediction of the clearance of ...... eonates, infants and children.
@ast
Prediction of the clearance of ...... eonates, infants and children.
@en
type
label
Prediction of the clearance of ...... eonates, infants and children.
@ast
Prediction of the clearance of ...... eonates, infants and children.
@en
prefLabel
Prediction of the clearance of ...... eonates, infants and children.
@ast
Prediction of the clearance of ...... eonates, infants and children.
@en
P2093
P1476
Prediction of the clearance of ...... eonates, infants and children.
@en
P2093
Amin Rostami-Hodjegan
Geoffrey T Tucker
Trevor N Johnson
P2860
P304
P356
10.2165/00003088-200645090-00005
P577
2006-01-01T00:00:00Z
P5875
P6179
1017122603